Sorafenib in Treating Patients With Advanced Malignant Solid Tumors

Phase 2 Completed 50 enrolled University of California, Davis Bayer · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects and best dose of sorafenib and to see how well it works in treating patients with advanced malignant solid tumors.

Timeline

Start: 2008-12
Primary completion: 2011-10
Completion: 2012-03

Publications

Results Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara PN Jr. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. Invest New Drugs. 2012 Oct;30(5):2001-7. doi: 10.1007/s10637-011-9761-y. Epub 2011 Oct 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	400 mg	Oral
Subject	Sorafenib	Small molecule	600 mg	Oral
Subject	Sorafenib	Small molecule	800 mg	Oral

Sorafenib in Treating Patients With Advanced Malignant Solid Tumors

Summary

Timeline

Publications

Drugs

Indications